PharmaShots Weekly Snapshot (September 02 - 06, 2019)
1.Roche's Tecentriq + Chemotherapy Receives EC's Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer
Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, Extensive Stage Small Cell Lung Cancer
2. OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer
Published: Sept 05, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology Program
Published: Sept 05, 2019 | Tags: BMS, Nivolumab, MGMT-Methylated Glioblastoma Multiforme, NewlyDiagnosed, Opdivo, P-III, Checkmate-548, Study, Patients, Reports, Results
Published: Sept 06, 2019 | Tags: Cantargia, Extends, Licensing Agreement, BioWa, POTELLIGENT Technology
5.AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor
Published: Sept 06, 2019 | Tags: AstraZeneca, Signs, License Agreement, Theragnostics, PARP Inhibitor
6.Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US
Published: Sept 06, 2019 | Tags: Takeda, Recalls, Natpara, parathyroid hormone, Injection, US
7.Roche's Tecentriq Based Combination Therapy Receives EC's Approval as 1L Treatment for Non-Squamous Non-Small Cell Lung Cancer
Published: Sept 06, 2019 | Tags: Roche, Tecentriq, EC, Approval, 1L, Treatment, Non-Squamous Non-Small Cell Lung Cancer
8.Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway
Published: Sept 05, 2019 | Tags: Novartis, Enters, Exclusive, Option Agreement, IFM Therapeutics, Develop, Therapies, Targeting, cGAS/STING Pathway
9.AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy
Published: Sept 04, 2019 | Tags: AbbVie, Signs, Research Agreement, Idera Pharmaceuticals, Evaluate; Combination Therapy
10.Janssen's Stelara (ustekinumab) Receives EC's Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis
Published: Sept 04, 2019 | Tags: Janssen, Stelara, ustekinumab, Receives, European Commission, Approval, Expanded Use, Moderately to Severely Active Ulcerative Colitis
11. BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis
Published: Sept 04, 2019 | Tags: BioNTech, Signs, Agreement, Gates Foundation, Develop, HIV, Tuberculosis
12.Google Collaborates with Cochlear and GN Hearing to Support Direct Phone Streaming to Hearing Aids for Patients with Hearing Loss
Published: Sept 05, 2019 | Tags: Google, Collaborates, Cochlear, GN Hearing, Support, Direct Phone Streaming, Hearing Aids
13.AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery
Published: Sept 04, 2019 | Tags: AstraZeneca, Collaborates, Schrödinger, Molecule-Modeling Platform, Drug Discovery
14.BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder
Published: Sept 04, 2019 | Tags: BMS, BioMotiv, Agreement, Serious Disorders, Develop, Therapies
15.Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314
Published: Sept 04, 2019 | Tags: Regenxbio, Signs, Exclusive, Worldwide, Option and License Agreement, Clearside Biomedical, Evaluate, Delivery Platform, RGX-314
Published: Sept 03, 2019 | Tags: Janssen, Investigational, Prophylactic Vaccine, Receives, US FDA, Breakthrough Therapy Designation, Respiratory Syncytial Virus
17.Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthma
Published: Sept 03, 2019 | Tags: Vivus, Reports, Results, Qsymia, Pilot Clinical Study, Patients, Laparoscopic Sleeve Gastrectomy Surgery
18. Merck's Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission's Approval as a 1L Therapy for Advanced Renal Cell Carcinoma
Published: Sept 04, 2019 | Tags: Merck, Keytruda, pembrolizumab, Inlyta, axitinib, European Commission, Approval, 1L, Therapy, Advanced Renal Cell Carcinoma
19.Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthma
Published: Sept 03, 2019 | Tags: Karolinska Institutet, Evaluates, AsthmaTuner, Self-monitoring, Mobile App, Uncontrolled Asthma
20.Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program
Published: Sept 04, 2019 | Tags: Boehringer Ingelheim, Enters, Licensing Agreement, Lupin, Expand, KRAS Cancer Program
21.AstraZeneca's Tagrisso (osimertinib) Receives NMPA's Approval as a 1L Therapy for EGFR-Mutated Non-Small Cell Lung Cancer in China
Published: Sept 04, 2019 | Tags: AstraZenca, Tagrisso, osimertinib, Receives, NMPA, Approval, 1L, Therapy, EGFR Mutated Non-Small Cell Lung Cancer, China
Published: Sept 03, 2019 | Tags: Celltrion, Enters, Contract to Manufacture, Agreement, Lonza, Biosimilar, Remsima
23.Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes
Published: Sept 03, 2019 | Tags: Vertex, Acquire, Semma Therapeutics, Developing, Curative Cell-Based Therapies, Type 1 Diabetes
24.Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity
Published: Sept 03, 2019 | Tags: Alytas Therapeutics, Signs, Agreement, Velabs Therapeutics, Develop, Novel, Immune-Based Therapy, Obesity
Published: Sept 02, 2019 | Tags: The European Society of Cardiology, Recommends, Bayer, Xarelto, rivaroxaban, Aspirin, Diabetes, Chronic Coronary Syndromes
26.Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis
Published: Sept 03, 2019 | Tags: Polpharma, Signs, Exclusive, Worldwide, Commercialization, Agreement, Sandoz, Proposed Biosimilar, Natalizumab, Relapsing-Remitting Multiple Sclerosis
27.Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America
Published: Sept 02, 2019 | Tags: Helsinn, Enters, Exclusive, Distribution, License, Agreement, Blanver, Varifarma, Pracinostat, South America
28. Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes
Published: Sept 03, 2019 | Tags: Boehringer Ingelheim, Zealand Pharma, Initiate, P-II Study, BI 456906, Obesity, Diabetes
29.AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure
Published: Sept 01, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
30.Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan
Published: Aug 30, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
31.AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes
Published: Sept 01, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
32.UniSA Evaluates Computer Vision Technology to Monitor Premature Babies in Neonatal Units
Published: Aug 30, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
33.Novartis Reports Results of Entresto (sacubitril/valsartan) in Three P-III PARAGON-HF and P-IV PROVE-HF with EVALUATE-HF Studies for Patients with HFpEF and HFrEF
Published: Aug 06, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
34.Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection
Published: Sept 02, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com